Probiotics and the Human Microbiome: Engineering Microbial Therapies for Chronic Diseases

Suzanne Vernon*

Department of Microbiology, Hardin-Simmons University, Abilene, USA

Commentary

Received: 27-Nov-2024, Manuscript No. JMB-24-157103; **Editor assigned:** 29-Nov-2024, PreQC No. JMB-24-157103 (PQ); **Reviewed:** 13-Dec-2024, QC No. JMB-24-157103; **Revised:** 20-Dec-2024, Manuscript No. JMB-24-157103 (R); **Published:** 27-Dec-2024, DOI: 10.4172/2320-3528.13.4.004.

***For Correspondence:** Suzanne Vernon, Department of Microbiology, Hardin-Simmons University, Abilene, USA

E-mail: suza.vera@gmail.com

Citation: Vernon S. Probiotics and the Human Microbiome: Engineering Microbial Therapies for Chronic Diseases. J Microbiol Biotechnol. 2023;13:004.

DESCRIPTION

The complex relationship between the human microbiome and overall health has attracted significant attention in recent years. The microbiome, comprising trillions of microorganisms residing in the human body, influences various physiological processes, including digestion, immunity and mental health. Among the approaches to utilize this microbial ecosystem for therapeutic purposes, probiotics have emerged as a promising tool. These live microorganisms, when administered in adequate amounts, confer health benefits to the host. In the context of chronic diseases, probiotics are being explored not only for their preventive potential but also as engineered therapies that target specific dysbiotic conditions.

Chronic diseases such as obesity, diabetes, cardiovascular diseases and Inflammatory Bowel Diseases (IBD) have been linked to disruptions in the microbiome, often referred to as dysbiosis. This imbalance in microbial communities can lead to inflammatory responses, impaired metabolic pathways, and weakened immune defence mechanisms. For instance, research has shown that individuals with type 2 diabetes often exhibit a reduced abundance of butyrate-producing bacteria, a microbial group vital for maintaining gut barrier integrity and modulating inflammation. Similarly, obesity has been associated with a lower diversity of gut microbiota, which impacts energy metabolism and fat storage.

Probiotics, traditionally used to promote gut health that are being repurposed to address specific microbiome-related dysfunctions in chronic diseases. These microorganisms including species of *Lactobacillus*, *Bifidobacterium* and *Saccharomyces* work by restoring microbial balance, enhancing gut barrier function and modulating immune responses. Their mechanisms of action include competitive inhibition of pathogenic bacteria, production of Short Chain Fatty Acids (SCFAs) and regulation of pro-inflammatory cytokines.

Recent studies highlight the role of probiotics in managing conditions such as IBD and Irritable Bowel Syndrome (IBS). In IBD, probiotics like *Lactobacillus rhamnosus* have been shown to reduce inflammation by suppressing nuclear factor pathways and enhancing the production of anti-inflammatory cytokines. Similarly, probiotic mixtures which have demonstrated efficacy in maintaining remission in ulcerative colitis patients. These findings underscore the potential of probiotics as adjunct therapies in chronic disease management.

While traditional probiotics have shown benefits, their effects are often limited by strain-specific properties and inter-individual variability. To address these challenges, advances in synthetic biology are being applied to engineer probiotics with enhanced functionalities. These engineered probiotics are designed to sense, respond to and modify the host's microbial environment in precise ways, clearing the path for personalized medicine.

For example, synthetic biology approaches have enabled the creation of probiotics that produce anti-inflammatory molecules like interleukin-10 (IL-10) directly in the gut. These modified strains can potentially provide targeted relief for conditions like crohn's disease, where systemic therapies often lead to undesirable side effects. Another notable innovation is the development of probiotics that can detect and neutralize pathogens or toxins in the gut, offering therapeutic benefits in infections and toxin-mediated disorders.

In the field of metabolic diseases, engineered probiotics have been used to modulate bile acid metabolism and improve glucose homeostasis. One promising example is the use of *Escherichia coli* engineered to secrete Glucagon-Like Peptide-1 (GLP-1), a hormone that regulates blood sugar levels. Such approaches demonstrate the potential to create highly targeted interventions that complement existing pharmacological treatments.

Despite the promising advancements, several challenges remain in the development and implementation of probiotic therapies for chronic diseases. One major hurdle is the variability in probiotic efficacy among individuals, driven by differences in baseline microbiome composition, diet and genetics. These factors necessitate the development of personalized probiotic therapies tailored to individual microbial and metabolic profiles.

Another challenge lies in ensuring the stability, viability and safety of engineered probiotics. For probiotics to exert their therapeutic effects, they must survive gastrointestinal transit, colonize the gut effectively and interact harmoniously with the existing microbiota. Advances in encapsulation technologies and strain engineering are addressing these issues, enhancing the delivery and functionality of probiotics.

Regulatory considerations also pose significant challenges. Unlike traditional probiotics, engineered strains often fall under the category of live bio therapeutic products, requiring rigorous clinical testing and regulatory approval. Establishing clear guidelines for safety evaluation in this field.

The future of probiotics in managing chronic diseases lies in integrating them into the broader landscape of microbiome based therapies. With advances in metagenomics, metabolomics and systems biology, it is becoming possible to gain deeper insights into host-microbe interactions and identify novel microbial targets for therapeutic interventions. This knowledge can guide the rational design of next-generation probiotics with enhanced efficacy and specificity.

Moreover, the combination of probiotics with prebiotics, dietary interventions and existing pharmacological therapies holds immense potential. Probiotics represent a transformative avenue in the management of chronic diseases by utilizing the therapeutic potential of the human microbiome. From traditional strains to engineered microbial therapies, the field has witnessed remarkable progress, driven by advances in science and technology. While challenges remain, the integration of probiotics into precision medicine holds the promise of revolutionizing healthcare. By addressing the complexities of dysbiosis and tailoring interventions to individual needs, probiotics can make the way for innovative, microbiome-based solutions to some of the most pressing chronic health issues of our time.